EDWARD ALLEN FISHER
Medical Practice in Scarsdale, NY

6201028, Mar 13, 2001

Dec 8, 1998

9/208613

Steven Shiff - New York NY
Edward A. Fisher - Scarsdale NY
I. Bernard Weinstein - Englewood NY
Hayes M. Dansky - Larchmont NY

The Rockefeller University - New York NY
Mt. Sinai School of Medicine - New York NY
Columbia University - New York NY

A01N 4340

514824

Methods and compositions for the prevention and/or treatment of cardiovascular diseases, the methods comprising administering to individuals in need thereof, an effective amount of a non-steroidal anti-inflammatory drug alone or in combination with other conventional therapies to induce apoptosis, reduce proliferation, induce quiescence, inhibit cell migration, or influence cell differentiation of the cells in the vascular wall and or/induce hypolipidemia.

6620853, Sep 16, 2003

Dec 8, 1999

09/456633

Steven Shiff - New York NY
Edward A. Fisher - Scarsdale NY
Hayes M. Dansky - Larchmont NY
Ernane Reis - New York NY

Mount Sinai School of Medicine - New York NY
The Rockefeller University - New York NY

A61K 31192

514708, 514568, 514569, 514570, 514420, 5142265, 514824

Methods and compositions for the prevention and/or treatment of vascular restenosis, the methods comprising administering to individuals in need thereof, an effective amount of a non-steroidal anti-inflammatory drug alone or in combination with other conventional therapies to induce apoptosis, reduce proliferation, induce quiescence, inhibit cell migration, or influence cell differentiation of the cells in the vascular wall and or/induce hypolipidemia.

2007029, Dec 20, 2007

May 2, 2007

11/799697

Jeffrey Brodsky - Pittsburgh PA, US
Edward Fisher - Scarsdale NY, US

University of Pittsburgh - Pittsburgh PA

A61K 38/00, A61P 43/00, C07H 21/04, C12N 1/00, C12N 5/00, C12Q 1/68, G01N 33/53

514044000, 435255100, 435325000, 435006000, 435007100, 435007900, 536023500, 536023720, 536023740

Hsp110 proteins are shown herein to stabilize nascent ApoB protein. Methods of down-regulating expression of ApoB, and thus down-regulating serum cholesterol levels, are therefore, provided, including, without limitation, inhibition of Hsp110 expression by any method, for example and without limitation, by RNA interference (RNAi). It also has been found that ApoB gene-containing cells are useful in identifying compounds and genes that affect the expression of longer forms of ApoB. Lastly, a firefly luciferase-derived polypeptide is shown herein to bind the peptide binding site of Hsp110, thus serving as a powerful analytical reagent for identifying compounds, such as small molecule compounds, that would interfere with Hsp110-moderated stabilization of ApoB.

8097283, Jan 17, 2012

Jan 14, 2005

10/557094

Edward A. Fisher - Scarsdale NY, US
Zahi A. Fayad - New York NY, US
Kevin J. Williams - Winnewood PA, US

Mount Sinai School of Medicine - New York NY

A61K 9/16

424498

The present invention is directed to synthetic nanoparticles useful as imaging agents for use in MRI, CT, Gamma-scintigraphy, or optical imaging techniques. The synthetic nanoparticles comprise at least one apolipoprotein that is not an apoB lipoprotein, at least one amphipathic lipid, and at least one metallic or non-metallic contrast agent linked through a chelator to a component of the nanoparticle, wherein the one metallic or non-metallic contrast agent is present in an amount of between 5% to about 50% (w/w) of the nanoparticle, and the nanoparticle has a diameter of from about 5 nm to about 50 nm. Compositions and kits comprising the synthetic nanoparticles and methods of making and using the same are also provided.

2003017, Sep 11, 2003

Mar 18, 2002

10/100823

Edward Fisher - Scarsdale NY, US
Kevin Williams - Wynnewood PA, US

C12Q001/68, A61K031/704, A61K031/455, A61K031/401, A61K031/366, A61K031/355, A61K031/225, A61K031/19

435/006000, 514/039000, 514/355000, 514/423000, 514/460000, 514/548000, 514/458000, 514/453000, 514/571000

The present invention involves a method of exploiting a novel apolipoprotein-B (apoB) degradation pathway to regulate plasma levels of apoB to treat cardiovascular or metabolic disorders or syndromes, a method of exploiting a novel apolipoprotein-B (apoB) degradation pathway to screen for drugs to treat cardiovascular or metabolic disorders or syndromes, and a method of exploiting a novel apolipoprotein-B (apoB) degradation pathway to screen for genes for diagnosing cardiovascular or metabolic disorders or syndromes.

7947307, May 24, 2011

Sep 16, 2005

11/228577

Edward A. Fisher - Scarsdale NY, US
Zahi A. Fayad - New York NY, US
Gwendalyn Randolph - New York NY, US
Jonathan Feig - Brooklyn NY, US
Eugene Trogan - Brooklyn NY, US

Mount Sinai School of Medicine of New York University - New York NY

A61K 9/14

424489, 977797, 977803, 977808, 977915, 977920, 977930

The present invention is directed to compositions useful as imaging agents for use in monitoring atherosclerotic plaque regression using, for example, MRI, CT, Gamma-scintigraphy, or optical imaging techniques. Methods and compositions of using the same are described.